Epidermal growth factor receptor: Mechanisms of activation and signalling

The EGF Receptor Family: Biologic Mechanisms and Role in Cancer

Volumn , Issue , 2003, Pages 33-55

  Jorissen, Robert N ^a,c   Walker, Francesca ^a,c   Pouliot, Normand ^a   Garrett, Thomas P J ^b,c   Ward, Colin W ^c,d   Burgess, Antony W ^a,c  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d CSIRO   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84881231371     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012160281-9/50004-9     Document Type: Chapter

References (293)

1. Carpenter G., Cohen S. Epidermal growth factor. J. Biol. Chem. 1990, 265:7709-7712.
2. Wells A. EGF receptor. Int. J. Biochem. Cell. Biol. 1999, 31:637-643.
3. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2001, 2:127-137.
4. Cohen S., Ushiro H., Stoscheck C., Chinkers M. A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles. J. Biol. Chem. 1982, 257:1523-1531.
5. Yarden Y., Schlessinger J. Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. Biochemistry 1987, 26:1443-1451.
6. Yarden Y., Schlessinger J. Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation. Biochemistry 1987, 26:1434-1442.
7. Honegger A.M., Kris R.M., Ullrich A., Schlessinger J. Evidence that autophosphorylation of solubilized receptors for epidermal growth factor is mediated by intermolecular cross-phosphorylation. Proc. Natl. Acad. Sci. USA 1989, 86:925-929.
8. Honegger A.M., Schmidt A., Ullrich A., Schlessinger J. Evidence for epidermal growth factor (EGF)-induced intermolecular autophosphorylation of the EGF receptors in living cells. Mol. Cell. Biol. 1990, 10:4035-4044.
9. Bogdan S., Klambt C. Epidermal growth factor receptor signaling. Curr. Biol. 2001, 11:R292-R295.
10. Hackel P.O., Zwick E., Prenzel N., Ullrich A. Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr. Opin. Cell. Biol. 1999, 11:184-189.
11. Mineo C., Gill G.N., Anderson R.G. Regulated migration of epidermal growth factor receptor from caveolae. J. Biol. Chem. 1999, 274:30636-30643.
12. Carpenter G., Cohen S. 1251-labeled human epidermal growth, factor. Binding internalization, and degradation in human fibroblasts. J. Cell. Biol. 1976, 71:159-171.
13. Beguinot L., Lyall R.M., Willingham M.C., Pastan I. Down-regulation of the epidermal growth factor receptor in KB cells is due to receptor internalization and subsequent degradation in lysosomes. Proc. Natl. Acad. Sci. USA 1984, 81:2384-2388.
14. Sorkin A., Waters C.M. Endocytosis of growth factor receptors. Bioessays 1993, 15:375-382.
15. Wiley H.S., Herbst J.J., Walsh B.J., Lauffenburger D.A., Rosenfeld M.G., Gill G.N. The role of tyrosine kinase activity in endocytosis, compartmentation, and down-regulation of the epidermal growth factor receptor. J. Biol. Chem. 1991, 266:11083-11094.
16. Lamaze C., Schmid S.L. Recruitment of epidermal growth factor receptors into coated pits requires their activated tyrosine kinase. J. Cell. Biol. 1995, 129:47-54.
17. Olayloye M.A., Neve R.M., Lane H.A., Hyne N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000, 19:3159-3167.
18. Garrett T.P., McKern N.M., Lou M., Elleman T.C., Adams T.E., Lovrecz G.O., Zhu H.J., Walker F., Frenkel M.J., Hoyne P.A., Jorissen R.N., Nice E.C., Burgess A.W., Ward C.W. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 2002, 110:763-773.
19. Ogiso H., Ishitani R., Nureki O., Fukai S., Yamanaka M., Kim J.H., Saito K., Sakamoto A., Inoue M., Shirouzu M., Yokoyama S. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002, 110:775-787.
20. Cho H.S., Leahy D.J. Structure of the extracellular region of HER 3 reveals an interdomain tether. Science 2002, 297:1330-1333.
21. Stamos J., Sliwkowski M.X., Eigenbrot C. Structure of the EGF receptor kinase domain alone and in complex with a4-anilinoquinazoline inhibitor. J. Biol. Chem. 2002, 277:46265-46272.
22. Ullrich A., Coussens L., Hayflick J.S., Dull T.J., Gray A., Tam A.W., Lee J., Yarden Y., Libermann T.A., Schlessinger J., Downward J., Mayes E.L.V., Whittle N., Waterfield M.D., Seeburg P.H. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984, 309:418-425.
23. Slieker L.J., Martensen T.M., Lane M.D. Synthesis of epidermal growth factor receptor in human A431 cells Glycosylation-dependent acquisition of ligand binding activity occurs post-translationally in the endoplasmic reticulum. J. Biol. Chem. 1986, 261:15233-15241.
24. Johns T.G., Stockert E., Ritter G., Jungbluth A.A., Huang H.J., Cavenee W.K., Smyth F.E., Hall C.M., Watson N., Nice E.C., Gullick W.J., Old L.J., Burgess A.W., Scott A.M. Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplitification of the EGFR gene. Int. J. Cancer. 2002, 98:398-408.
25. Garrett T.P., McKern N.M., Lou M., Frenkel M.J., Bentley J.D., Lovreez G.O., Elleman T.C., Cosgrove L.J., Ward C.W. Crystal structure of the first three domains of the type-1 insulin-like growth factor receptor. Nature 1998, 394:395-399.
26. Elleman T.C., Domagala T., McKern N.M., Nerrie M., Lonnqvist B., Adams T.E., Lewis J., Lovrecz G.O., Hoyne P.A., Richards K.M., Howlett G.J., Rothacker J., Jorissen R.N., Lou M., Garrett T.P., Burgess A.W., Nice E.C., Ward C.W. Identification of a determinant of epidermal growth factor receptor ligand-binding specificity using a truncated, high-affinity form of the ectodomain. Biochemistry 2001, 40:8930-8939.
27. Yamabhai M., Anderson R.G. Second cysteine-rich region of epidermal growth factor receptor contains targeting information for caveolae/rafts. J. Biol. Chem. 2002, 277:24843-24846.
28. Rigby A.C., Grant C.W., Shaw G.S. Solution and solid state conformation of the human EGF receptor transmembrane region. Biochim. Biophys. Acta. 1998, 1371:241-253.
29. Kil S.J., Carlin C. EGF receptor residues leu(679), leu(680) mediate selective sorting of ligand-receptor complexes in early endosomal compartments. J. Cell. Physiol. 2000, 185:47-60.
30. He C., Hobert M., Friend L., Cardin C. The epidermal growth factor receptor juxtamembrane domain has multiple basolateral plasma membrane localization determinants, including a dominant signal with a polyproline core. J. Biol. Chem. 2002, 277:38284-38293.
31. Castagnino P., Biesova Z., Wong W.T., Fazioli F., Gill G.N., Di Fiore P.P. Direct binding of eps8 to the juxtamembrane domain of EGFR is phosphotyrosine- and SH2-independent. Oncogene 1995, 10:723-729.
32. Martin-Nieto J., Villalobo A. The human epidermal growth factor receptor contains a juxtamembrane calmodulin-binding site. Biochemistry 1998, 37:227-236.
33. Li H., Villalobo A. Evidence for the direct interaction between calmodulin and the human epidermal growth factor receptor. Biochem. J. 2002, 362:499-505.
34. Hubbard S.R. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J. 1997, 16:5572-5581.
35. Den Hartigh J.C., Van Bergen En Henegouwen P.M., Verkleij A.J., Boonstra J. The EGF receptor is an actin-binding protein. J. Cell. Biol. 1992, 119:349-355.
36. Kuan C.T., Wikstrand C.J., Bigner D.D. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr. Relat. Cancer 2001, 8:83-96.
37. Huang H.S., Nagane M., Klingbeil C.K., Lin H., Nishikawa R., Ji X.D., Huang C.M., Gill G.N., Wiley H.S., Cavenee W.K. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unatenuated signaling. J. Biol. Chem. 1997, 272:2927-2935.
38. Weber W., Gill G.N., Spiess J. Production of an epidermal growth factor receptor-related protein. Science 1984, 224:294-297.
39. Ilekis J.V., Stark B.C., Scoccia B. Possible role of variant RNA transcripts in the regulation of epidermal growth factor receptor expression in human placenta. Mol. Reprod. Dev. 1995, 41:149-156.
40. Ilekis J.V., Gariti J., Niederberger C., Scoccia B. Expression of a truncated epidermal growth factor receptor-like protein (TEGFR) in ovarian cancer. Gynecol. Oncol. 1997, 65:36-41.
41. Reiter J.L., Maihle N.J. A 1,8kb alternative transcript from the human epidermal growth factor receptor gene encodes a truncated form of the receptor. Nucleic Acids. Res. 1996, 24:4050-4056.
42. Groenen L.C., Nice E.C., Burgess A.W. Structure-function relationships for the EGF/TGF-alpha family of mitogens. Growth Factors 1994, 11:235-257.
43. Nice E.C., Domagala T., Fabri L., Nerriea M., Walker F., Jorissen R.N., Burgess A.W., Cui D.F., Zhang Y.S. Rapid microscale enzymic semisynthesis of epidermal growth factor (EGF) analogues. Growth Factors 2002, 20:71-80.
44. Strachan L., Murison J.G., Prestidge R.L., Sleeman M.A., Watson J.D., Kumble K.D. Cloning and biological activity of epigen, a novel member of the epidermal growth factor superfamily. J. Biol. Chem. 2001, 276:18265-18271.
45. Thompson S.A., Harris A., Hoang D., Ferrer M., Johnson G.R. COOH-terminal extended recombinant amphiregulin with bioactivity comparable with naturally derived growth factor. J. Biol. Chem. 1996, 271:17927-17931.
46. Neelam B., Richter A., Chamberlin S.G., Puddicombe S.M., Wood L., Murray M.B., Nandagopal K., Niyogi S.K., Davies D.E. Structure-function studies of ligand-induced epidermal growth factor receptor dimerization. Biochemistry 1998, 37:4884-4891.
47. Jones J.T., Akita R.W., Sliwkowski M.X. Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett. 1999, 447:227-231.
48. Harari D., Tzahar E., Romano J., Shelly M., Pierce J.H., Andrews G.C., Yarden Y. Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase. Oncogene 1999, 18:2681-2689.
49. Kohda D., Odaka M., Lax I., Kawasaki H., Suzuki K., Ullrich A., Schlessinger J., Inagaki F. A 40-kDa epidermal growth factor/transforming growth factor alpha-binding domain produced by limited proteolysis of the extracellular domain of the epidermal growth factor receptor. J. Biol. Chem. 1993, 268:1976-1981.
50. Lemmon M.A., Bu Z., Ladbury J.E., Zhou M., Pinchasi D., Lax I., Engelman D.M., Schlessinger J. Two EGF molecules contribute additively to stabilization of the EGFR dimer. EMBO J. 1997, 16:281-294.
51. Kim J.H., Saito K., Yokoyama S. Chimeric receptor analyses of the interactions of the ectodomains of ErbB-1 with epidermal growth factor and of those of ErbB-4 with neuregulin. Eur. J. Biochem. 2002, 269:2323-2329.
52. Singer E., Landgraf R., Horan T., Slamon D., Eisenberg D. Identification of a heregulin binding site in HER3 extracellular domain. J. Biol. Chem. 2001, 276:44266-44274.
53. Barbacci E.G., Guarino B.C., Stroh J.G., Singleton D.H., Rosnack K.J., Moyer J.D., Andrews G.C. The structural basis for the specificity of epidermal growth factor and heregulin binding. J. Biol. Chem. 1995, 270:9585-9589.
54. Harris A., Adler M., Brink J., Lin R., Foehr M., Ferrer M., Langton-Webster B.C., Harkins R.N., Thompson S.A. Homologue scanning mutagenesis of heregulin reveals receptor specific binding epitopes. Biochem. Biophys. Res. Commun. 1998, 251:220-224.
55. Stortelers C., Souriau C., van Liempt E., van de Poll M.L., van Zoelen E.J. Role of the N-terminus of epidermal growth factor in ErbB-2/ErbB-3 binding studied by phage display. Biochemistry 2002, 41:8732-8741.
56. Adler M., Thompson S.A. The solution structure of heregulin-alpha and a N-terminal mutant with suppressed activity. Biochem. Biophys. Res. Commun. 1999, 256:156-161.
57. Beerli R.R., Hynes N.E. Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities. J. Biol. Chem. 1996, 271:6071-6076.
58. Lin C.R., Chen W.S., Lazar C.S., Carpenter C.D., Gill G.N., Evans R.M., Rosenfeld M.G. Protein kinase C phosphorylation at Thr 654 of the unoccupied EGF receptor and EGF binding regulate functional receptor loss by independent mechanisms. Cell 1986, 44:839-848.
59. Boni-Schnetzler M., Pilch P.F. Mechanism of epidermal growth factor receptor autophosphorylation and high-affinity binding. Proc. Natl. Acad. Sci. USA 1987, 84:7832-7836.
60. Hurwitz D.R., Emanuel S.L., Nathan M.H., Sarver N., Ullrich A., Felder S., Lax I., Schlessinger J. EGF induces increased ligand binding affinity and dimerization of soluble epidermal growth factor (EGF) receptor extracellular domain. J. Biol. Chem. 1991, 266:22035-22043.
61. Sorokin A., Lemmon M.A., Ullrich A., Schlessinger J. Stabilization of an active dimeric form of the epidermal growth factor receptor by introduction of an inter-receptor disulfide bond. J. Biol. Chem. 1994, 269:9752-9759.
62. Martin-Fermandez M., Clarke D.T., Tobin M.J., Jones S.V., Jones G.R. Preformed oligomeric epidermal growth factor receptors undergo an ectodomain structure change during signaling. Biophys. J. 2002, 82:2415-2427.
63. Prywes R., Livneh E., Ullrich A., Schlessinger J. Mutations in the cytoplasmic domain of EGF receptor affect EGF binding and receptor internalization. EMBO J. 1986, 5:2179-2190.
64. Fowler K.J., Walker F., Alexander W., Hibbs M.L., Nice E.C., Bohmer R.M., Mann G.B., Thumwood C., Maglitto R., Danks J.A. A mutation in the epidermal growth factor receptor in waved-2 mice has a profound effect on receptor biochemistry that results in impaired lactation. Proc. Natl. Acad. Sci. USA 1995, 92:1465-1469.
65. Groenen L.C., Walker F., Burgess A.W., Treutlein H.R. A model for the activation of the epidermal growth factor receptor kinase involvement of an asymmetric dimer?. Biochemistry 1997, 36:3826-3836.
66. Walker F., Hibbs M.L., Zhang H.H., Gonez L.J., Burgess A.W. Biochemical characterization of mutant EGF receptors expressed in the hemopoietic cell line B aF/3. Growth Factors 1998, 16:53-67.
67. Van der Heyden M.A., Nievers M., Verkleij A.J., Boonstra J., Van Bergen En Henegouwen P.M. Identification of an intracellular domain of the EGF receptor required for high-affinity binding of EGF. FEBS Lett. 1997, 410:265-268.
68. Walker F., Burgess A.W. Reconstitution of the high affinity epidermal growth factor receptor on cell-free membranes after transmodulation by platelet-derived growth factor. J. Biol. Chem. 1991, 266:2746-2752.
69. Holbrook M.R., Slakey L.L., Gross D.J. Thermodynamic mixing of molecular states of the epidermal growth factor receptor modulates macroscopic ligand binding affinity. Biochem. J. 2000, 352(Pt 1):99-108.
70. Odaka M., Kohda D., Lax I., Schlessinger J., Inagaki F. Ligand-binding enhances the affinity of dimerization of the extracellular domain of the epidermal growth factor receptor. J. Biochem. (Tokyo) 1997, 122:116-121.
71. Domagala T., Konstantopoulos N., Smyth F., Jorissen R.N., Fabri L., Geleick D., Lax I., Schlessinger J., Sawyer W., Howlett G.J., Burgess A.W., Nice E.C. Stoichiometry, kinetic and binding analysis of the interaction between epidermal growth factor (EGF) and the extracellular domain of the EGF receptor. Growth Factors 2000, 18:11-29.
72. Sako Y., Minoghchi S., Yanagida T. Single-molecule imaging of EGFR signalling on the surface of living cells. Nat. Cell. Biol. 2000, 2:168-172.
73. Moriki T., Maruyama H., Maruyama I.N. Activation of preformed EGF receptor dimers by ligand-induced rotation of the transmembrane domain. J. Mol. Biol. 2001, 311:1011-1026.
74. Berezov A., Chen J., Liu Q., Zhang H.T., Greene M.I., Murali R. Disabling receptor ensembles with rationally designed interface peptidomimetics. J. Biol. Chem. 2002, 277:28330-28339.
75. Schlessinger J. Dynamics of hormone receptors on cell membrane. Ann. NY Acad. Sci. 1981, 366:274-284.
76. Chantry A. The kinase domain and membrane localization determine intracellular interactions between epidermal growth factor receptors. J. Biol. Chem. 1995, 270:3068-3073.
77. Tanner K.G., Kyte J. Dimerization of the extracellular domain of the receptor for epidermal growth factor containing the membrane-spanning segment in response to treatment with epidermal growth factor. J. Biol. Chem. 1999, 274:35985-35990.
78. Graus-Porta D., Beerli R.R., Daly J.M., Hynes N.E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997, 16:1647-1655.
79. Karunagaran D., Tzahar E., Beerli R.R., Chen X., Graus-Porta D., Katzkin B.J., Seger R., Hynes N.E., Yarden Y. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 1996, 15:254-264.
80. Lenferink A.E., Pinkas-Kramarski R., van de Poll M.L., Vugt M.J.van, Klapper L.N., Tzahar E., Waterman H., Sela M., Zoelen E.J.van, Yarden Y. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J. 1998, 17:3385-3397.
81. Huang G.C., Ouyang X., Epstein R.J. Proxy activation of protein ErbB2 by heterologous ligands implies a heterotetrameric mode of receptor tyrosine kinase interaction. Biochem. J. 1998, 331(Pt 1):113-119.
82. Ferguson K.M., Darling P.J., Mohan M.J., Macatee T.L., Lemmon M.A. Extracellular domains drive homo- but not heterodimerization of erbB receptors. EMBO J 2000, 19:4632-4643.
83. Gamett D.C., Pearson G., Cerione R.A., Friedberg I. Secondary dimerization between members of the epidermal growth factor receptor family. J. Biol. Chem. 1997, 272:12052-12056.
84. Johannessen L.E., Haugen K.E., Ostvold A.C., Stang E., Madshus I.H. Heterodimerization of the epidermal-growth-factor (EGF) receptor and ErbB2 and the affinity of EGF binding are regulated by different mechanisms. Biochem. J. 2001, 356:87-96.
85. Saifo Y., Haendeler J., Hojo Y., Yamamoto K., Berk B.C. Receptor heterodimerization: essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation. Mol. Cell. Biol. 2001, 21:6387-6394.
86. Gadella T.W., Jovin T.M. Oligomerization of epidermal growth factor receptors on A431 cells studied by time-resolved fluorescence imaging microscopy. A stereochemical model for tyrosine kinase receptor activation. J. Cell. Biol. 1995, 129:1543-1558.
87. Yu X., Sharma K.D., Takahashi T., Iwamoto R., Mekada E. Ligand-independent dimer formation of epidermal growth factor receptor (EGFR) is a step separable from ligand-induced EGFR signaling. Mol. Biol. Cell. 2002, 13:2547-2557.
88. Humphrey P.A., Wong A.J., Vogelstein B., Friedman H.S., Werner M.H., Bigner D.D., Bigner S.H. Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res 1988, 48:2231-2238.
89. Yamazaki H., Fukui Y., Ueyama Y., Tamaoki N., Kawamoto T., Taniguchi S., Shibuya M. Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors. Mol. Cell. Biol. 1988, 8:1816-1820.
90. Malden L.T., Novak U., Kaye A.H., Burgess A.W. Selective amplification of the cytoplasmic domain of the epidermal growth factor receptor gene in glioblastoma multiforme. Cancer Res. 1988, 48:2711-2714.
91. Kwatra M.M., Bigner D.D., Cohn J.A. The ligand binding domain of the epidermal growth factor receptor is not required for receptor dimerization. Biochim. Biophys. Acta 1992, (1134):178-181.
92. Ekstrand A.J., Longo N., Hamid M.L., Olson J.J., Liu L., Collins V.P., Jarnes C.D. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 1994, 9:2313-2320.
93. Fernandes H., Cohen S., Bishayee S. Glycosylation-induced conformational modification positively regulates receptor-receptor association a study with an aberrant epidermal growth factor receptor (EGFRvIII/DeltaEGFR) expressed in cancer cells. J. Biol. Chem. 2001, 276:5375-5383.
94. Canals F. Signal transmission by epidermal growth factor receptor coincidence of activation and dimerization. Biochemistry 1992, 31:4493-4501.
95. Sherrill J.M. Insufficiency of self-phosphorylation for the activation of epidermal growth factor receptor. Biochemistry 1997, 36:5677-5684.
96. Hubbard S.R., Mohammadi M., Schlessinger J. Autoregulatory mechanisms in protein-tyrosine kinases. J. Biol. Chem. 1998, 273:11987-11990.
97. Tice D.A., Biscardi J.S., Nickles A.L., Parsons S.J. Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc. Natl. Acad. Sci. USA 1999, 96:1415-1420.
98. Yamaguchi H., Hendrickson W.A. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature 1996, 384:484-489.
99. Arteaga C.L., Ramsey T.T., Shawver L.K., Guyer C.A. Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site. J. Biol. Chem. 1997, 272:23247-23254.
100. Lichtner R.B., Menrad A., Sommer A., Klar U., Schneider M.R. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res. 2001, 61:5790-5795.
101. Montgomery R.B. Antagonistic and agonistic effects of quinazoline tyrosine kinase inhibitors on mutant EGF receptor function. Int. J. Cancer 2002, 101:111-117.
102. Huse M., Kuriyan J. The conformational plasticity of protein kinases. Cell 2002, 109:275-282.
103. Ge G., Wu J., Wang Y., Lin Q. Activation mechanism of solubilized epidermal growth factor receptor tyrosine kinase. Biochem. Biophys. Res. Commun. 2002, 290:914-920.
104. Daly R.J. Take your partner, please-signal diversification by the erbB family of receptor tyrosine kinases. Growth Factors 1999, 16:255-263.
105. Deb T.B., Su L., Wong L., Bonvini E., Wells A., David M., Johnson G.R. Epidermal growth factor (EGF) receptor kinase-independent signaling by EGF. J. Biol. Chem. 2001, 276:15554-15560.
106. Ewald J.A., Coker K.J., Price J.O., Staros J.V., Guyer C.A. Stimulation of mitogenic pathways through kinase-impaired mutants of the epidermal growth factor receptor. Exp. Cell. Res. 2001, 268:262-273.
107. Yamauchi T., Ueki K., Tobe K., Tamemoto H., Sekine N., Wada M., Honjo M., Takahashi M., Takahashi T., Hirai H., Tushima T., Akanuma Y., Fujita T., Komuro I., Yazaki Y., Kadowaki T. Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone. Nature 1997, 390:91-96.
108. Fukazawa T., Miyake S., Band V., Band H. Tyrosine phosphorylation of Cb1 upon epidermal growth factor (EGF) stimulation and its association with EGF receptor and downstream signaling proteins. J. Biol. Chem. 1996, 271:14554-14559.
109. Wheeler M., Domin J. Recruitment of the class II phosphoinositide 3-kinase C2beta to the epidermal growth factor receptor role of Grb2. Mol. Cell. Biol. 2001, 21:6660-6667.
110. Kloth M.T., Laughlin K.K., Biscardi J.S., Boerner J.L., Parsons S.J., Silva C.M. STAT5b, a mediator of synergism between c-Src and the EGF receptor. J. Biol. Chem. 2003, 278:1671-1679.
111. Hellyer N.J., Cheng K., Koland J.G. ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase. Biochem. J. 1998, 333(Pt 3):757-763.
112. Galcheva-Gargova Z., Konstantinov K.N., Wu I.H., Klier F.G., Barrett T., Davis R.J. Binding of zinc finger protein ZPR1 to the epidermal growth factor receptor. Science 1996, 272:1795-1797.
113. Xia L., Wang L., Chung A.S., Ivanov S.S., Ling M.Y., Dragoi A.M., Platt A., Gilmer T.M., Fu X.Y., Chin Y.E. Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation. J. Biol. Chem. 2002, 277:30716-30723.
114. Olayioye M.A., Beuvink I., Horsch K., Daly J.M., Hynes N.E. ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J. Biol. Chem. 1999, 274:17209-17218.
115. Walker F., Kato A., Gonez L.J., Hibbs M.L., Pouliot N., Levitzki A., Burgess A.W. Activation of the Ras/mitogen-activated protein kinase pathway by kinase-defective epidermal growth factor receptors results in cell survival but not proliferation. Mol. Cell. Biol. 1998, 18:7192-7204.
116. Walton G.M., Chen W.S., Rosenfeld M.G., Gill G.N. Analysis of deletions of the carboxyl terminus of the epidermal growth factor receptor reveals self-phosphorylation at tyrosine 992 and enhanced in vivo tyrosine phosphorylation of cell substrates. J. Biol. Chem. 1990, 265:1750-1754.
117. Gotoh N., Tojo A., Muroya K., Hashimoto Y., Hattori S., Nakamura S., Takenawa T., Yazaki Y., Shibuya M. Epidermal growth factor-receptor mutant lacking the autophosphorylation sites induces phosphorylation of She protein and She-Grb2/ASH association and retains mitogenic activity. Proc. Natl. Acad. Sci. USA 1994, 91:167-171.
118. Wong L., Deb T.B., Thompson S.A., Wells A., Johnson G.R. A differential requirement for the COOH-terminal region of the epidermal growth factor (EGF) receptor in amphiregulin and EGF mitogenic signaling. J. Biol. Chem. 1999, 274:8900-8909.
119. Stover D.R., Becker M., Liebetanz J., Lydon N.B. Src phosphorylation of the epidermal growth factor receptor at novel sites mediates receptor interaction with Src and P85 alpha. J. Biol. Chem. 1995, 270:15591-15597.
120. Lowenstein E.J., Daly R.J., Batzer A.G., Li W., Margolis B., Lammers R., Ullrich A., Skolnik E.Y., Bar-Sagi D., Schlessinger J. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell 1992, 70:431-442.
121. Batzer A.G., Rotin D., Urena J.M., Skolnik E.Y., Schlessinger J. Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. Mol. Cell. Biol. 1994, 14:5192-5201.
122. Sasaoka T., Langlois W.J., Leitner J.W., Draznin B., Olefsky J.M. The signaling pathway coupling epidermal growth factor receptors to activation of p2 tras. J. Biol. Chem. 1994, 269:32621-32625.
123. Sakaguchi K., Okabayashi Y., Kido Y., Kimura S., Matsumura Y., Inushima K., Kasuga M. Shc phosphotyrosine-binding domain dominantly interacts with epidermal growth factor receptors and mediates Ras activation in intact cells. Mol. Endocrinol. 1998, 12:536-543.
124. Hashimoto A., Kurosaki M., Gotoh N., Shibuya M., Kurosaki T. She regulates epidermal growth factor-induced activation of the JNK signaling pathway. J. Biol. Chem. 1999, 274:20139-20143.
125. Hallberg B., Rayter S.I., Downward J. Interaction of Ras and Raf in intact mammalian cells upon extracellular stimulation. J. Biol. Chem. 1994, 269:3913-3916.
126. Johnson G.L., Vaillancourt R.R. Sequential protein kinase reactions controlling cell growth and differentiation. Curr. Opin. Cell. Biol. 1994, 6:230-238.
127. Langlois W.J., Sasaoka T., Saltiel A.R., Olefsky J.M. Negative feedback regulation and desensitization of insulin- and epidermal growth factor-stimulated p21ras activation. J. Biol. Chem. 1995, 270:25320-25323.
128. Jun T., Gjoerup O., Roberts T.M. Tangled webs: evidence of cross-talk between c-Raf-1 and Akt. Sci STKE 1999, 1999. El.
129. Liebmann C. Regulation of MAP kinase activity by peptide receptor signalling pathwayparadigms of multiplicity. Cell. Signal. 2001, 13:777-785.
130. Pouyssegur J., Volmat V., Lenormand P. Fidelity and spatiotemporal control in MAP kinase (ERKs) signalling. Biochem. Pharmacol. 2002, 64:755-763.
131. Meisner H., Czech M.P. Coupling of the proto-oncogene product c-Cbl to the epidermal growth factor receptor. J. Biol. Chem. 1995, 270:25332-25335.
132. Schlaepfer D.D., Hauck C.R., Sieg D.J. Signaling through focal adhesion kinase. Prog. Biophys. Mol. Biol. 1999, 71:435-478.
133. Xu X.X., Yi T., Tang B., Lambeth J.D. Disabled-2 (Dab2) is an SH3 domain-binding partner of Grb2. Oncogene 1998, 16:1561-1569.
134. Sepulveda P.De, Okkenhaug K., Rose J.L., Hawley R.G., Dubreuil P., Rottapel R. Socs1 binds to multiple signalling proteins and suppresses steel factor-dependent proliferation. EMBO J. 1999, 18:904-915.
135. Harmer S.L., DeFranco A.L. The src homology domain 2-containing inositol phosphatase SHIP forms a ternary complex with She and Grb2 in antigen receptor-stimulated B lymphocytes. J. Biol. Chem. 1999, 274:12183-12191.
136. Pelicci G., Lanfrancone L., Salcini A.E., Romano A., Mele S., Grazia B.M., Segatto O., Fiore P.P.Di, Pelicci P.G. Constitutive phosphorylation of Shc proteins in human tumors. Oncogene 1995, 11:899-907.
137. Pomerance M., Multon M.C., Parker F., Venot C., Blondeau J.P., Tocque B., Schweighoffer F. Grb2 interaction with MEK-kinase 1 is involved in regulation of Jun-kinase 1 is involved in regulation of Jun-kinase activities in response to epidermal growth factor. J. Biol. Chem. 1998, 273:24301-24304.
138. Xu Y., Guo D.F., Davidson M., Inagami T., Carpenter G. Interaction of the adaptor protein Shc and the adhesion molecule cadherin. J. Biol. Chem. 1997, 272:13463-13466.
139. Damelin M., Silver P.A. Mapping interactions between nuclear transport factors in living cells reveals pathways through the nuclear pore complex. Mol. Cell. 2000, 5:133-140.
140. Belsches A.P., Haskell M.D., Parsons S.J. Role of c-Src tyrosine kinase in EGF-induced mitogenesis. Front. Biosci. 1997, 2:d501-d518.
141. Luttrell D.K., Luttrell L.M., Parsons S.J. Augmented mitogenic responsiveness to epidermal growth factor in murine fibroblasts that overexpress pp60c-src. Mol. Cell. Biol. 1988, 8:497-501.
142. Maa M.C., Leu T.H., McCarley D.J., Schatzman R.C., Parsons S.J. Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers. Proc. Natl. Acad. Sci. USA 1995, 92:6981-6985.
143. Roche S., Koegl M., Barone M.V., Roussel M.F., Courtneidge S.A. DNA synthesis induced by some but not all growth factors requires Src family protein tyrosine kinases. Mol. Cell. Biol. 1995, 15:1102-1109.
144. Barone M.V., Courtneidge S.A. Myc but not Fos rescue of PDGF signalling block caused by kinase-inactive Src [see comments]. Nature 1995, 378:509-512.
145. Karni R., Jove R., Levitzki A. Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. Oncogene 1999, 18:4654-4662.
146. Osherov N., Levitzki A. Epidermal-growth-factor-dependent activation of the src-family kinases. Eur. J. Biochem. 1994, 225:1047-1053.
147. Mao W., Irby R., Coppola D., Fu L., Wloch M., Turner J., Yu H., Garcia R., Jove R., Yeatman T.J. Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene 1997, 15:3083-3090.
148. Biscardi J.S., Maa M.C., Tice D.A., Cox M.E., Leu T.H., Parsons S.J. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J. Biol. Chem. 1999, 274:8335-8343.
149. Lombardo C.R., Consler T.G., Kassel D.B. In vitro phosphorylation of the epidermal growth factor receptor autophosphorylation domain by c-src: identification of phosphorylation sites and c-src SH2 domain binding sites. Biochemistry 1995, 34:16456-16466.
150. Sato K., Sato A., Aoto M., Fukami Y. c-Src phosphorylates epidermal growth factor receptor on tyrosine 845. Biochem. Biophys. Res. Commun. 1995, 215:1078-1087.
151. Kendall R.L., Rutledge R.Z., Mao X., Tebben A.J., Hungate R.W., Thomas K.A. Vascular endothelial growth factor receptor KDR tyrosine kinase activity is increased by autophosphorylation of two activation loop tyrosine residues. J. Biol. Chem. 1999, 274:6453-6460.
152. Cunningham M.E., Greene L.A. A function-structure model for NGF-activated TRK. EMBO J. 1998, 17:7282-7293.
153. Gotoh N., Tojo A., Hino M., Yakazi Y., Shibuya M. A highly conserved tyrosine residue at codon 845 within the kinase domain is not required for the transforming activity of human epidermal growth factor receptor. Biochem. Biophys. Res. Commun. 1992, 186:768-774.
154. Wright J.D., Reuter C.W., Weber M.J. An incomplete program of cellular tyrosine phosphorylations induced by kinase-defective epidermal growth factor receptors. J. Biol. Chem. 1995, 270:12085-12093.
155. Sato K., Gotoh N., Otsuki T., Kakumoto M., Aoto M., Tokmakov A.A., Shibuya M., Fukami Y. Tyrosine residues 239 and 240 of Shc are phosphatidylinositol 4,5-bisphosphate-dependent phosphorylation sites by c-Src. Biochem. Biophys. Res. Commun. 1997, 240:399-404.
156. Chang J.H., Gill S., Settleman J., Parsons S.J. c-Src regulates the simultaneous rearrangement of actin cytoskeleton, p190RhoGAP, and p120RasGAP following epidermal growth factor stimulation. J. Cell. Biol. 1995, 130:355-368.
157. Roof R.W., Haskell M.D., Dukes B.D., Sherman N., Kinter M., Parsons S.J. Phosphotyrosine (p-Tyr)-dependent and -independent mechanisms of p190 RhoGAP-p120 RasGAP interaction: Tyr 1105 of p190, a substrate for c-Src, is the sole p-Tyr mediator of complex formation. Mol. Cell. Biol. 1998, 18:7052-7063.
158. Nojima Y., Mimura T., Morino N., Hamasaki K., Furuya H., Sakai R., Nakamoto T., Yazaki Y., Hirai H. Tyrosine phosphorylation of p130Cas in cell adhesion and transformation. Hum. Cell 1996, 9:169-174.
159. Huang C., Liu J., Haudenschild C.C., Zhan X. The role of tyrosine phosphorylation of cortactin in the locomotion of endothelial cells. J. Biol. Chem. 1998, 273:25770-25776.
160. Lohi O., Lehto V.P. EAST, a novel EGF receptor substrate, associates with focal adhesions and actin fibers. FEBS Lett. 1998, 436:419-423.
161. Provenzano C., Gallo R., Carbone R., Di Fiore P.P., Falcone G., Castellani L., Alema S. Eps8, a tyrosine kinase substrate, is recruited to the cell cortex and dynamic F-actin upon cytoskeleton remodeling. Exp. Cell. Res. 1998, 242:186-200.
162. Shoelson S.E., Sivaraja M., Williams K.P., Hu P., Schlessinger J., Weiss M.A. Specific phosphopeptide binding regulates a conformational change in the PI3-kinase SH2 domain associated with enzyme activation. EMBO J. 1993, 12:795-802.
163. Damell J.E. STATs and gene regulation. Science 1997, 277:1630-1635.
164. Ihle J.N., Nosaka T., Thierfelder W., Quelle F.W., Shimoda K. Jaks and Stats in cytokine signaling. Stem Cells 1997, 15(Suppl 1):105-111.
165. Leonard W.J. Role of Jak kinases and STATs in cytokine signal transduction. Int. J. Hematol. 2001, 73:271-277.
166. Park O.K., Schaefer T.S., Nathans D. In vitro activation of Stat3 by epidermal growth factor receptor kinase. Proc. Natl. Acad. Sci. USA 1996, 93:13704-13708.
167. David M., Wong L., Flavell R., Thompson S.A., Wells A., Larner A.C., Johnson G.R. STAT activation by epidermal growth factor (EGF) and amphiregulin. Requirement for the EGF receptor kinase but not for tyrosine phosphorylation sites or JAK1. J. Biol. Chem. 1996, 271:9185-9188.
168. Leaman D.W., Pisharody S., Flickinger T.W., Commane M.A., Schlessinger J., Kerr I.M., Levy D.E., Stark G.R. Roles of JAKs in activation of STATs and stimulation of c-fos gene expression by epidermal growth factor. Mol. Cell. Biol. 1996, 16:369-375.
169. Houle M.G., Bourgoin S. Regulation of phospholipase D by phosphorylation-dependent mechanisms. Biochim. Biophys. Acta 1999, 1439:135-149.
170. Slaaby R., Jensen T., Hansen H.S., Frohman M.A., Seedorf K. PLD2 complexes with the EGF receptor and undergoes tyrosine phosphorilation at a single site upon agonist stimulation. J. Biol. Chem. 1998, 273:33722-33727.
171. Hemandez-Sotomayor S.M., Carpenter G. Non-catalytic activation of phospholipase C-gamma 1 in vitro by epidermal growth factor receptor. Biochem. J. 1993, 293(Pt 2):507-511.
172. Kamat A., Carpenter G. Phospholipase C-gamma1: regulation of enzyme function and role in growth factor-dependent signal transduction. Cytokine Growth Factor Rev. 1997, 8:109-117.
173. Chattopadhyay A., Vecchi M., Ji Q., Mernaugh R., Carpenter G. The role of individual SH2 domains in mediating association of phospholipase C-gamma 1 with the activated EGF receptor. J. Biol. Chem. 1999, 274:26091-26097.
174. Wahl M., Nishibe S., Kim J.W., Kim H., Rhee S.G., Carpenter G. Identification of two epidermal growth factor-sensitive tyrosine phosphorylation sites of phospholipase C-gamma in intact HSC-1 cells. J. Biol. Chem. 1990, 265:3944-3948.
175. Hofer F., Berdeaux R., Martin G.S. Ras-independent activation of Ral by a Ca(2+)-dependent pathway. Curr. Biol. 1998, 8:839-842.
176. Sun L., Carpenter G. Epidermal growth factor activation of NF-kappaB is mediated through IkappaBalpha degradation and intracellular free calcium. Oncogene 1998, 16:2095-2102.
177. Marais R., Light Y., Mason C., Paterson H., Olson M.F., Marshall C.J. Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C. Science 1998, 280:109-112. [published erratum appears in Science 1998 May 15;280(5366): 987].
178. McClellan M., Kievit P., Auersperg N., Rodland K. Regulation of proliferation and apoptosis by epidermal growth factor and protein kinase C in human ovarian surface epithelial cells. Exp. Cell. Res. 1999, 246:471-479.
179. Liaw Y.S., Yang P.C., Yu C.J., Kuo S.H., Luh K.T., Lin Y.J., Wu M.L. PKC activation is required by EGF-stimulated Na(+)-H+exchanger in human pleural mesothelial cells. Am. J. Physiol. 1998, 274:L665-L672.
180. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 2002, 296:1655-1657.
181. Djordjevic S., Driscoll P.C. Structural insight into substrate specificity and regulatory mechanisms of phosphoinositide 3-kinases. Trends. Biochem. Sci. 2002, 27:426-432.
182. Carpenter C.L., Auger K.R., Chanudhuri M., Yoakim M., Schaffhausen B., Shoelson S., Cantley L.C. Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85-kDa subunit. J. Biol. Chem. 1993, 268:9478-9483.
183. Kim H.H., Sierke S.L., Koland J.G. Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product. J. Biol. Chem. 1994, 269:24747-24755.
184. Ram T.G., Ethier S.P. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification. Cell. Growth. Differ. 1996, 7:551-561.
185. Jones P.F., Jakubowicz T., Pitossi F.J., Maurer F., Hemmings B.A. Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc. Natl. Acad. Sci. USA 1991, 88:4171-4175.
186. Nicholson K.M., Anderson N.G. The protein kinase B/Akt signalling pathway in human malignancy. Cell. Signal. 2002, 14:381-395.
187. Pacold M.E., Suire S., Perisic O., Lara-Gonzalez S., Davis C.T., Walker E.H., Hawkins P.T., Stephens L., Eccleston J.F., Williams R.L. Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell 2000, 103:931-943.
188. Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the newborn animal. J. Biol. Chem. 1962, 237:1555-1562.
189. Gregory H. Isolation and structure of urogastrone and its relationship to epidermal growth factor. Nature 1975, 257:325-327.
190. de Larco J.E., Todaro G.J. Growth factors from murine sarcoma virus-transformed cells. Proc. Natl. Acad. Sci. USA 1978, 75:4001-4005.
191. Smith J.M., Sporn M.B., Roberts A.B., Derynck R., Winkler M.E., Gregory H. Human transforming growth factor-alpha causes precocious eyelid opening in newborm mice. Nature 1985, 315:515-516.
192. Topham R.T., Chiego D.J.J., Gattone V.H., Hinton D.A., Klein R.M. The effect of epidermal growth factor on neonatal incisor differentiation in the mouse. Dev. Biol. 1987, 124:532-543.
193. Calamandrei G., Alleva E. Epidermal growth factor has both growth-promoting and growth-inhibiting effects on physical and neurobehavioral development of neonatal mice. Brain Res. 1989, 477:1-6.
194. Smart J.L., da S.V., Malheiros L.R., Paumgartten F.J., Massey R.F. Epidermal growth factor advances some aspects of development but retards others in both rats and hamsters. J. Dev. Physiol. 1989, 11:153-158.
195. Vassar R., Fuchs E. Transgenic mice provide new insights into the role of TGF-alpha during epidermal development and differentiation. Genes Dev. 1991, 5:714-727.
196. Dominey A.M., Wang X.J., King L.E.J., Nanney L.B., Gagne T.A., Sellheyer K., Bundman D.S., Longley M.A., Rothnagel J.A., Greenhalgh D.A. Targeted overexpression of transforming growth factor alpha in the epidermis of transgenic mice elicits hyperplasia, hyperkeratosis, and spontaneous, squamous papillomas. Cell Growth Differ. 1993, 4:1071-1082.
197. Cook P.W., Piepkorn M., Clegg C.H., Plowman G.D., DeMay J.M., Brown J.R., Pittelkow M.R. Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotype. J. Clin. Invest. 1997, 100:2286-2294.
198. Lowden D.A., Lindemann G.W., Merlino G., Barash B.D., Calvet J.P., Gattone V.H. Renal cysts in transgenic mice expressing transforming growth factor-alpha [see comments]. J. Lab. Clin. Med. 1994, 124:386-394.
199. Gattone V.H., Kuenstler K.A., Lindemann G.W., Lu X., Cowley B.D.J., Rankin C.A., Calvet J.P. Renal expression of a transforming growth factor-alpha transgene accelerates the progression of inherited, slowly progressive polycystic kidney disease in the mouse. J. Lab. Clin. Med. 1996, 127:214-222.
200. Davies B.R., Platt-Higgins A.M., Schmidt G., Rudland P.S. Development of hyperplasias, preneoplasias, and mammary tumors in MMTV-c-erbB-2 and MMTV-TGF alpha transgenic rats. Am. J. Pathol. 1999, 155:303-314.
201. Sandgren E.P., Schroeder J.A., Qui T.H., Palmier R.D., Brinster R.L., Lee D.C. Inhibition of mammary gland involution is associated with transforming growth factor alpha but not c-myc-induced tumorigenesis in transgenic mice. Cancer Res. 1995, 55:3915-3927.
202. Hehir D.J., McGreal G., Kirwan W.O., Kealy W., Brady M.P. c-myc oncogene expression a marker for females at risk of breast carcinoma. J. Surg. Oncol. 1993, 54:207-209.
203. Visscher D.W., Wallis T., Awussah S., Mohamed A., Crissman J.D. Evaluation of MYC and chromosome 8 copy number in breast carcinoma by interphase cytogenetics. Genes Chromosomes Cancer 1997, 18:1-7.
204. Bieche I., Lidereau R. Genetic alterations in breast cancer. Genes Chromosomes Cancer 1995, 14:227-251.
205. Amundadottir L.T., Nass S.J., Berchem G.J., Johnson M.D., Dickson R.B. Cooperation of TGF alpha and c-Myc in mouse mammary tumorigenesis: coordinated stimulation of growth and suppression of apoptosis. Oncogene 1996, 13:757-765.
206. Murakami H., Sanderson N.D., Nagy P., Marino P.A., Merlino G., Thorgeirsson S.S. Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis. Cancer Res. 1993, 53:1719-1723.
207. Thorgeirsson S.S., Santoni-Rugiu E. Interaction of c-myc with transforming growth factor alpha and hepatocyte growth factor in hepatocarcinogenesis. Mutat. Res. 1997, 376:221-234.
208. Santoni-Rugiu E., Jensen M.R., Thorgeirsson S.S. Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transferming growth factor alpha. Cancer Res. 1998, 58:123-134.
209. Sargent L.M., Sanderson N.D., Thorgeirsson S.S. Ploidy and karyotypic alterations associated with early events in the development of hepatocarcinogenesis in transgenic mice harboring c-myc and transforming growth factor alpha transgenes. Cancer Res 1996, 56:2137-2142.
210. Schlegel J., Merdes A., Stumm G., Albert F.K., Forsung M., Hynes N., Kiessling M. Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma. Int. J. Cancer 1994, 56:72-77.
211. Moscatello D.K., Holgado-Madruga M., Godwin A.K., Ramirez G., Gunn G., Zoltick P.W., Biegel J.A., Hayes R.L., Wong A.J. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 1995, 55:5536-5539.
212. Sugawa N., Ekstrand A.J., James C.D., Collins V.P. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc. Natl. Acad. Sci. USA 1990, 87:8602-8606.
213. Ekstrand A.J., Sugawa N., James C.D., Collins V.P. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc. Natl. Acad. Sci. USA 1992, 89:4309-4313.
214. Nishikawa R., Ji X.D., Harmon R.C., Lazar C.S., Gill G.N., Cavenee W.K., Huang H.J. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl. Acad. Sci. USA 1994, 91:7727-7731.
215. Nagane M., Coufal F., Lin H., Bogler O., Cavenee W.K., Huang H.J. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res. 1996, 56:5079-5086.
216. Holland E.C., Hively W.P., DePinho R.A., Varmus H.E. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev. 1998, 12:3675-3685.
217. Bachoo R.M., Maher E.A., Ligon K.L., Sharpless N.E., Chan S.S., You M.J., Tang Y., DeFrances J., Stover E., Weissleder R., Rowitch D.H., Louis D.N., DePinho R.A. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell. 2002, 1:269-277.
218. Okamoto S., Oka T. Evidence for physiological function of epidermal growth factor: pregestational sialoadenectomy of mice decreases milk production and increases offspring mortality during lactation period. Proc. Natl. Acad. Sci. USA 1984, 81:6059-6063.
219. Tsutsumi O., Kubota Y., Oka T. Effect of sialoadenectomy, treatment with epidermal growth factor (EGF) antiserum and replacement of EGF on the epidermis in mice. J. Endocrinol. 1987, 113:193-197.
220. Luetteke N.C., Qiu T.H., Peiffer R.L., Oliver P., Smithies O., Lee D.C. TGF alpha deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice. Cell 1993, 73:263-278.
221. Mann G.B., Fowler K.J., Gabriel A., Nice E.C., Williams R.L., Dunn A.R. Mice with a null mutation of the TGF alpha gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation. Cell 1993, 73:249-261.
222. Blum M. A null mutation in TGF-alpha leads to a reduction in midbrain dopaminergic neurons in the substantia nigra. Nat. Neurosci. 1998, 1:374-377.
223. Luetteke N.C., Qiu T.H., Fenton S.E., Troyer K.L., Riedel R.F., Chang A., Lee D.C. Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development 1999, 126:2739-2750.
224. Threadgill D.W., Dlugosz A.A., Hansen L.A., Tennenbaum T., Lichti U., Yee D., LaMantia C., Mourton T., Herrup K., Harris R.C. Targeted disruption of mouse EGF receptor: effect of genetic back-ground on mutant phenotype. Science 1995, 269:230-234.
225. Sibilia M., Wagner E.F. Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 1995, 269:234-238. [published erratum appears in Science 1995 Aug 18;269(5226):909].
226. Miettinen P.J., Berger J.E., Meneses J., Phung Y., Pedersen R.A., Werb Z., Derynck R. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 1995, 376:337-341.
227. Luetteke N.C., Phillips H.K., Qiu T.H., Copeland N.G., Earp H.S., Jenkins N.A., Lee D.C. The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase. Genes Dev. 1994, 8:399-413.
228. Xie W., Paterson A.J., Chin E., Nabell L.M., Kudlow J.E. Targeted expression of a dominant negative epidermal growth factor receptor in the mammary gland of transgenic mice inhibits pubertal mammary duct development. Mol. Endocrinol. 1997, 11:1766-1781.
229. Wiesen J.F., Young P., Werb Z., Cunha G.R. Signaling through the stromal epidermal growth factor receptor is necessary for mammary ductal development. Development 1999, 126:335-344.
230. Lauffenburger D.A., Horwitz A.F. Cell migration: a physically integrated molecular process. Cell 1996, 84:359-369.
231. Mitchison T.J., Cramer L.P. Actin-based cell motility and cell locomotion. Cell 1996, 84:371-379.
232. Kaverina I., Krylyshkina O., Small J.V. Regulation of substrate adhesion dynamics during cell motility. Int. J. Biochem. Cell. Biol. 2002, 34:746-761.
233. Kumar C.C. Signaling by integrin receptors. Oncogene 1998, 17:1365-1373.
234. Dedhar S. Cell-substrate interactions and signaling through ILK. Curr. Opin. Cell. Biol. 2000, 12:250-256.
235. Giancotti E.G., Ruoslahti E. Integrin signaling. Science 1999, 285:1028-1032.
236. Matsumoto K., Ziober B.L., Yao C.C., Kramer R.H. Growth factor regulation of integrin-mediated cell motility. Cancer Metastasis Rev. 1995, 14:205-217.
237. Iijima M., Huang Y.E., Devreotes P. Temporal and spatial regulation of chemotaxis. Dev. Cell. 2002, 3:469-478.
238. Wells A., Gupta K., Chang P., Swindle S., Glading A., Shiraha H. Epidermal growth factor receptor-mediated motility in fibroblasts. Microsc. Res. Tech. 1998, 43:395-411.
239. Hudson L.G., McCawley L.J. Contributions of the epidermal growth factor receptor to keratinocyte motility. Microsc. Res. Tech. 1998, 43:444-455.
240. Wells A. Tumor invasion: role of growth factor-induced cell motility. Adv. Cancer Res. 2000, 78:31-101.
241. Kassis J., Lauffenburger D.A., Turner T., Wells A. Tumor invasion as dysregulated cell motility. Semin. Cancer Biol. 2001, 11:105-117.
242. Chen P., Xie H., Sekar M.C., Gupta K., Wells A. Epidermal growth factor receptor-mediated cell motility: phospholipase C activity is required, but mitogen-activated protein kinase activity is not sufficient for induced cell movement. J. Cell. Biol. 1994, 127:847-857.
243. Chen P., Gupta K., Wells A. Cell movement elicited by epidermal growth factor receptor requires kinase and autophosphorylation but is separable from mitogenesis. J. Cell. Biol. 1994, 124:547-555.
244. Chen P., Murphy-Ullrich J.E., Wells A. A role for gelsolin in actuating epidermal growth factor receptor-mediated cell motility. J. Cell Biol. 1996, 134:689-698.
245. van Leeuwen F.N., van Delft S., Kain H.E., van der Kammen R.A., Collard J.G. Rac regulates phosphorylation of the myosin-II heavy chain, actinomyosin disassembly and cell spreading. Nat. Cell. Biol. 1999, 1:242-248.
246. Hughes P.E., Renshaw M.W., Pfaff M., Forsyth J., Keivens V.M., Schwartz M.A., Ginsberg M.H. Supression of integrin activationa novel function of a Ras/Raf-initiated MAP kinase pathway. Cell 1997, 88:521-530.
247. Xie H., Pallero M.A., Gupta K., Chang P., Ware M.F., Witke W., Kwiatkowski D.J., Lauffenburger D.A., Murphy-Ullrich J.E., Wells A. EGF receptor regulation of cell motility: EGF induces disassembly of focal adhesions independently of the motility-associated PLC gamma signaling pathway. J. Cell. Sci. 1998, 111(Pt 5):615-624.
248. Sheetz M.P., Felsenfeld D.P., Galbraith C.G. Cell migration: regulation of force on extracellularl-matrix-integrin complexes. Trends Cell. Biol. 1998, 8:51-54.
249. Huttenlocher A., Palecek S.P., Lu Q., Zhang W., Mellgren R.L., Lauffenburger D.A., Ginsberg M.H., Horwitz A.F. Regulation of cell migration by the calcium-dependent protease calpain. J. Biol. Chem. 1997, 272:32719-32722.
250. Shiraha H., Glading A., Gupta K., Wells A. IP-10 inhibits epidermal growth factor-induced motility by decreasing epidermal growth factor receptor-mediated calpain activity. J. Cell. Biol. 1999, 146:243-254.
251. Palecek S.P., Loftus J.C., Ginsberg M.H., Lauffenburger D.A., Horwitz A.F. Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness. Nature 1997, 385:537-540.
252. Glading A., Lauffenburger D.A., Wells A. Cutting to the chase: calpain proteases in cell motility. Trends Cell. Biol. 2002, 12:46-54.
253. Lee J., Ishihara A., Oxford G., Johnson B., Jacobson K. Regulation of cell movement is mediated by stretch-activated calcium channels. Nature 1999, 400:382-386.
254. Klemke R.L., Cai S., Giannini A.L., Gallagher P.J., de Lanerolle P., Cheresh D.A. Regulation of cell motility by mitogen-activated protein kinase. J. Cell. Biol. 1997, 137:481-492.
255. Bresnick A.R. Molecular mechanisms of nonmuscle myosin-II regulation. Curr. Opin. Cell. Biol. 1999, 11:26-33.
256. Zamir E., Katz B.Z., Aota S., Yamada K.M., Geiger B., Kam Z. Molecular diversity of cell-matrix adhesions. J. Cell. Sci. 1999, 112(Pt 11):1655-1669.
257. Verbeek B.S., Adriaansen-Slot S.S., Vroom T.M., Beckers T., Rijksen G. Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. FEBS Lett. 1998, 425:145-150.
258. Theodorescu D., Laderoute K.R., Gulding K.M. Epidermal growth factor receptor-regulated human bladder cancer motility is in part a phosphatidylinositol 3-kinase-mediated process. Cell. Growth Differ. 1998, 9:919-928.
259. Wu C.J., Chen Z., Ullrich A., Greene M.I., O'Rourke D.M. Inhibition of EGFR-mediated phosphoinositide-3-OH kinase (P13-K) signaling and glioblastoma phenotype by signal-regulatory proteins (SIRPs). Oncogene 2000, 19:3999-4010.
260. Hall A. Rho GTPases and the actin cytoskeleton. Science 1998, 279:509-514.
261. Aspenstrom P. Effectors for the Rho GTPases. Curr. Opin. Cell. Biol. 1999, 11:95-102.
262. Schoenwaelder S.M., Burridge K. Bidirectional signaling between the cytoskeleton and integrins. Curr. Opin. Cell. Biol. 1999, 11:274-286.
263. Nobes C.D., Hall A. Rho GTPases control polarity, protrusion, and adhesion during cell movement. J. Cell. Biol. 1999, 144:1235-1244.
264. Malliri A., Symons M., Hennigan R.F., Hurlstone A.F., Lamb R.F., Wheeler T., Ozanne B.W. The transcription factor AP-1 is required for EGF-induced activation of rho-like GTPases, cytoskeletal rearrangements, motility, and in vitro invasion of A431 cells. J. Cell. Biol. 1998, 143:1087-1099.
265. Keely P.J., Westwick J.K., Whitehead I.P., Der C.J., Parise L.V. Cdc42 and Racl induce integrin-mediated cell motility and invasiveness through PI(3)K. Nature 1997, 390:632-636.
266. Keely P., Parise L., Juliano R. Integrins and GTPases in tumour cell growth, motility and invasion. Trends Cell. Biol. 1998, 8:101-106.
267. Rameh L.E., Cantley L.C. The role of phosphoinositide 3-kinase lipid products in cell function. J. Biol. Chem. 1999, 274:8347-8350.
268. Leevers S.J., Vanhaesebroeck B., Waterfield M.D. Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Curr. Opin. Cell. Biol. 1999, 11:219-225.
269. Hawkins P.T., Eguinoa A., Qiu R.G., Stokoe D., Cooke F.T., Walters R., Wennstrom S., Claesson-Welsh L., Evans T., Symons M., Stephens L. PDGF stimulates an increase in GTP-Rac via activation of phosphoinositide 3-kinase. Curr. Biol. 1995, 5:393-403.
270. Han J., Luby-Phelps K., Das B., Shu X., Xia Y., Mosteller R.D., Krishna U.M., Falck J.R., White M.A., Broek D. Role of substrates and products of PI 3-kinase in regulating activation of Rac-related guanosine triphosphatases by Vav. Science 1998, 279:558-560.
271. Greenwood J.A., Theibert A.B., Prestwich G.D., Murphy-Ullrich J.E. Restructuring of focal adhesion plaques by PI 3-kinase Regulation by Ptdlns (3,4,5)-p(3) binding to alpha-actinin. J. Cell. Biol. 2000, 150:627-642.
272. Piccolo E., Innominato P.F., Mariggio M.A., Maffucci T., Iacobelli S., Falasca M. The mechanism involved in the regulation of phospholipase C gammal activity in cell migration. Oncogene 2002, 21:6520-6529.
273. Weiner O.D. Rac activation P-Rex1-a convergence point for PIP(3) and Gbetagamma?. Curr. Biol. 2002, 12:R429-R431.
274. Porter A.C., Vaillancourt R.R. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene 1998, 17:1343-1352.
275. Corvera S., Czech M.P. Direct targets of phosphoinositide 3-kinase products in membrane traffic and signal transduction. Trends, Cell. Biol. 1998, 8:442-446.
276. Nathke I.S., Adams C.L., Polakis P., Sellin J.H., Nelson W.J. The adenomatous polyposis coli tumor suppressor protein localizes to plasma membrane sites involved in active cell migration. J. Cell. Biol. 1996, 134:165-179.
277. Fenton J.I., Wolff M.S., Orth M.W., Hord N.G. Membrane-type matrix metalloproteinases mediate curcumin-induced cell migration in non-tumorigenic colon epithelial cells differing in Apc genotype. Carcinogenesis 2002, 23:1065-1070.
278. Ware M.F., Wells A., Lauffenburger D.A. Epidermal growth factor alters fibroblast migration speed and directional persistence reciprocally and in a matrix-dependent manner. J. Cell. Sci. 1998, 111(Pt 16):2423-2432.
279. Gu J., Tamura M., Pankov R., Danen E.H., Takino T., Matsumoto K., Yamada K.M. She and FAK differentially regulated cell motility and directionality modulated by PTEN. J. Cell. Biol. 1999, 146:389-403.
280. Zhao M., Dick A., Forrester J.V., McCaig C.D. Electric field-directed cell motility involves up-regulated expression and asymmetric redistribution of the epidermal growth factor receptors and is enhanced by fibronectin and laminin. Mol. Biol. Cell. 1999, 10:1259-1276.
281. Fang K.S., Ionides E., Oster G., Nuccitelli R., Isseroff R.R. Epidermal growth factor receptor relocalization and kinase activity are necessary for directional migration of keratinocytes in DC electric fields. J. Cell. Sci. 1999, 112(Pt 12):1967-1978.
282. Zhao M., Pu J., Forrester J.V., McCaig C.D. Membrane lipids, EGF receptors, and intracellular signals colocalized and are polarized in epithelial cells moving directionally in a physiological electric field. FASEB J. 2002, 16:857-859.
283. Li J., Lin M.L., Wiepz G.J., Guadarrame A.G., Bertics P.J. Integrin-mediated migration of murine B82L fibroblasts is dependent on the expression of an intact epidermal growth factor receptor. J. Biol. Chem. 1999, 274:11209-11219.
284. Okutani T., Okabayashi Y., Kido Y., Sugimoto Y., Sakaguchi K., Matuoka K., Takenawa T., Kasuga M. Grb2/Ash binds directly to tyrosines 1068 and 1086 and indirectly to tyrosine 1148 of activated human epidermal growth factor receptors in intact cells. J. Biol. Chem. 1994, 269:31310-31314.
285. McCarty J.H. The Nck SH2/SH3 adaptor protein: a regulator of multiple intracellular signal transduction events. Bioessays 1998, 20:913-921.
286. Hashimoto Y., Katayama H., Kiyokawa E., Ota S., Kurata T., Gotoh N., Otsuka N., Shibata M., Matsuda M. Phosphorylation of CrkII adaptor protein at tyrosine 221 by epidermal growth factor receptor. J. Biol. Chem. 1998, 273:17186-17191.
287. Jones N., Dumont D.J. Recruitment of Dok-R to the EGF receptor through its PTB domain is required for attenuation of Erk MAP kinase activation. Curr. Biol. 1999, 9:1057-1060.
288. Serth J., Weber W., Frech M., Wittinghofer A., Pingoud A. Binding of the H-ras p21 GTPase activating protein by the activated epidermal growth factor receptor leads to inhibition of the p21 GTPase activity in vitro. Biochemistry 1992, 31:6361-6365.
289. Milarski K.L., Zhu G., Pearl C.G., McNamara D.J., Dobrusin E.M., MacLean D., Thieme-Sefler A., Zhang Z.Y., Sawyer T., Decker S.J. Sequence specificity in recognition of the epidermal growth factor receptor by protein tyrosine phosphatase 1B. J. Biol. Chem. 1993, 268:23634-23639.
290. Keilhack H., Tenev T., Nyakatura E., Godovac-Zimmermann J., Nielsen L., Seedorf K., Bohmer F.D. Phosphotyrosine 1173 mediates binding of the protein-tyrosine phosphatase SHP-1 to the epidermal growth factor receptor and attenuation of receptor signaling. J. Biol. Chem. 1998, 273:24839-24846.
291. Zhu G., Decker S.J., MacLean D., McNamara D.J., Singh J., Sawyer T.K., Saltiel A.R. Sequence specificity in the recognition of the epidermal growth factor receptor by the ab1 Src homology 2 domain. Oncogene 1994, 9:1379-1385.
292. Kraulis P.J. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 1991, 24:946-950.
293. Merritt E.A., Bacon D.J. Raster 3D: photorealistic molecular graphics. Methods Enzymol. 1997, 277:505-524.